{"contentid": 487899, "importid": NaN, "name": "Germany's Merck sees blockbuster potential in xevinapant", "introduction": "A major global licensing agreement will see Merck KGaA take possession of xevinapant, a first-in-class cancer medicine.", "content": "<p>A major global licensing agreement will see Merck KGaA (MRK: DE) take possession of xevinapant, a first-in-class cancer medicine.</p>\n<p>Swiss firm Debiopharm has released promising Phase II data for the candidate, which show a statistically-significant impact in certain people with head and neck cancer.</p>\n<p>Under the terms of the deal, Debiopharm will receive 188 million euros ($225 million) up-front, plus up to 710 million euros in regulatory and commercial milestones, plus royalties.</p>\n<p>The deal gives Merck full development and commercialization rights to the drug, an oral inhibitor of apoptosis proteins.</p>\n<p>The drug is currently being investigated in the Phase III TrilynX study, enrolling people with previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with chemo and radiotherapy.</p>\n<p>Peter Guenter, chief executive of Merck&rsquo;s healthcare division, said the drug could be &ldquo;an important new treatment option in an area of high unmet need where other approaches, including immunotherapy, have seen limited success.&rdquo;</p>\n<p>He added: &ldquo;The promising long-term efficacy of xevinapant in the Phase II trial suggests that antagonism of IAP has the potential to be a transformative approach in this cancer.&rdquo;</p>\n<p>Merck plans to kick off a second global Phase III study, to evaluate xevinapant in people with the same cancer, who are unable to tolerate high-dose cisplatin and radiotherapy.</p>", "date": "2021-03-01 10:47:00", "meta_title": NaN, "meta_keywords": "Merck, xevinapant, cancer, global, Phase, million, Germany, blockbuster, sees, major, agreement, KGaA, possession, first-in-class, potential, licensing", "meta_description": "A major global licensing agreement will see Merck KGaA take possession of xevinapant, a first-in-class cancer medicine.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-01 10:46:44", "updated": "2021-03-01 11:03:26", "access": NaN, "url": "https://www.thepharmaletter.com/article/germany-s-merck-sees-blockbuster-potential-in-xevinapant", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merck_kgaa_new_large.jpg", "image2id": "merck_kgaa_new_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Oncology", "topic_tag": "Deals, Drug Trial, Licensing, Research", "geography_tag": "Germany, Switzerland", "company_tag": "Debiopharm, Merck KGaA", "drug_tag": "xevinapant", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-01 10:47:00"}